



WD 9P.1614
Sequence 1798

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Simantov, et al.

Examiner: Unassigned

Serial No.: 09/730,379

Group Art Unit: 1614

Filed: December 5, 2000

Attorney's Docket: 955-7P COM

For: THROMBOSPONDIN-BINDING
REGION OF HISTIDINE-RICH
GLYCOPROTEIN AND
METHODS OF USE

Dated: March 14, 2001

I hereby certify this correspondence is being de-
posited with the United States Postal Service as first
class mail, postpaid in an envelope, addressed to:
Assistant Commissioner for Patents, Washington, D.C.

Assistant Commissioner for Patents
Washington, D.C. 20231

20231 on March 14, 2001
Dated: 3/14/01 J. B. Bagnoni

INFORMATION DISCLOSURE STATEMENT

Sir:

In compliance with their obligations under 37 C.F.R. 1.56, 1.97 and 1.98, Applicants
bring to the attention of the Examiner the references listed below.

UNITED STATES PATENTS

<u>PATENTEE</u>	<u>PATENT NUMBER</u>	<u>ISSUE DATE</u>
Tuszynski	5,367,059	November 22, 1994
Frazier et al.	5,399,667	March 21, 1995
Frazier et al.	5,627,265	May 6, 1997
Cech et al.	6,025,167	February 15, 2000
Bennett et al.	6,150,162	November 22, 2000

FOREIGN PATENTS

<u>COUNTRY/OFFICE</u>	<u>PUBLICATION NO.</u>	<u>PUBLICATION DATE</u>
PCT	WO 93/22340	11 November 1993


NON-PATENT REFERENCES (ARTICLES)

1. Dawson et al., "CD36 Mediates the In Vitro Inhibitory Effects of Thrombospondin-1 on Endothelial Cells", J. Cell Biol., 138:707-17.
2. Chen et al., "Antibody Blockade of Thrombospondin Accelerates Reendothelialization and Reduces Neointima Formation in Balloon-Injured Rat Carotid Artery", Circulation, 100:849-854.
3. Gao et al., "Integrin-Associated Protein is a Receptor for the C-Terminal Domain of Thrombospondin", J Biol Chem., 1996 Jan 18; 271(1):21-4: Abstract provided.
4. Wang et al., Thrombospondin-1 modulates angiogenesis in vitro by up-regulation of matrix metalloproteinase-9 in endothelial cells", Exp Cell Res. 235(2):403-12 (1997). Abstract provided.
5. Tuszynski et al., "The role of thrombospondin-1 in tumor progression and angiogenesis", Bioessays, 18(1):71-6 (1996). Abstract provided.
6. Gewirtz, et al., "Nucleic Acid Therapeutics: State of the Art and Future Prospects", Blood, 19(3): 712-736 (1998). Review article.

The above-listed references are also listed on Applicants' Substitute Form PTO-1449, which is attached to this Information Disclosure Statement.

As a result of this submission, Applicants respectfully submit that the application is
in all respects in condition for examination on the merits.

Respectfully submitted,

A handwritten signature in cursive script, reading "Algis Anilionis", written over a horizontal line.

Algis Anilionis, Ph.D.

Reg. No. 36,995

Attorney for Applicant(s)

HOFFMANN & BARON, LLP
6900 Jericho Turnpike
Syosset, New York 11791
(516) 822-3550
AA:jb

129781_1.DOC